Clinical Trials Browser

Withdrawn × Interventional × atezolizumab × Clear all

NCT06713798 2026-03-23

INDIGO

Phase 2 Withdrawn

Lung Neoplasms

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase 2 Withdrawn

Carcinoma, Squamous Cell

NCT06416436 2025-06-29

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Phase 1 Withdrawn

Neoplasm Metastasis

NCT06719973 2025-06-17

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Phase 1 Withdrawn

Other solid neoplasm

Advanced Solid Tumors

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT06331598 2024-12-24

IMperator

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Other solid neoplasm

Select Advanced Solid Tumors

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05510427 2023-08-15

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Phase 1 Withdrawn

Gastrointestinal

Liver Neoplasms, Cholangiocarcinoma

NCT05109052 2023-07-13

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04510584 2023-06-06

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms

NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

NCT05327738 2022-12-14

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT04630210 2022-06-15

AteBrO

Phase EARLY_PHASE1 Withdrawn

Breast Neoplasms

NCT05007769 2021-11-05

RAN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04020094 2021-09-22

AtezoVax

Phase 2 Withdrawn

Prostate Adenocarcinoma

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03786419 2021-05-13

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Thoracic Neoplasms

NCT04267237 2021-02-04

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04272645 2020-07-15

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03498222 2020-02-25

iTRAP

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03973879 2020-02-11

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Phase 1/2 Withdrawn

Brain Neoplasms, Glioblastoma, Glioma

NCT03818997 2020-02-05

DYNAMIC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

NCT03693573 2018-11-15

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3 Withdrawn

Carcinoma, Renal Cell

NCT03340558 2018-10-09

ATELIER

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03369964 2018-04-05

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Withdrawn

Lymphoma, Non-Hodgkin

NCT02495636 2017-06-22

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung